Weekly Digest - 24-30 Jun 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 24-30 Jun 2023
29 June 2023: RenovoGem (intra-arterial administration of gemcitabine) / RenovoRx: Reported positive interim Phase 3 data
- Phase 3 TIGeR-PaC study of intra-arterial gemcitabine vs. IV gemcitabine and nab-paclitaxel following radiotherapy for LAPC (n=320)
- Results:
- Efficacy: n= 45 (23 pts in RenovoGem vs 22 pts in SoC arm)
- mPFS: 15 months vs 7 months
- mOS: 16 months vs 10 months
- Safety:
- >65% reduction in adverse events vs SOC
- Efficacy: n= 45 (23 pts in RenovoGem vs 22 pts in SoC arm)
- RenovoGem is built on the TAMPä (Trans-arterial Micro-perfusion) therapy platform
- Delivers gemcitabine directly to the tumor site, potentially enhancing the therapeutic effect while potentially minimizing the systemic side effects, commonly associated with traditional chemotherapy (IV) administration, and improving patient outcomes
- TIGeR-PaC is currently enrolling unresectable locally Advanced Pancreatic Cancer (LAPC) patients at several sites across the US
- “Placing patients at the center of everything we do is a critical focus. We are thrilled to announce these pivotal TIGeR-PaC study results supporting RenovoGem’s meaningful clinical benefit and impressive safety profile for patients with LAPC,” said Shaun Bagai, CEO, RenovoRx
